Evolution of the prostate cancer genome towards resistance

Abstract

The clinical behavior of prostate cancer is highly heterogeneous, with most patients diagnosed with localized disease that successfully responds to surgery or radiotherapy or that can be followed by active surveillance. However, a fraction of men will relapse after initial treatment and eventually progress to an aggressive resistant form with metastasis spreading and high mortality, a state referred to as castration resistant prostate cancer (CRPC). The technological advances in next generation sequencing have enabled the deep genomic and epigenomic characterization of both the hormone naïve and CRPC states, leading to the definition of molecular subclasses of prostate cancer that could inform the clinicians on therapeutic strategies. These studies also shed light on the mechanisms driving resistance to therapy. CRPCs adapt to androgen receptor (AR) signaling impairment - which follows first-line therapies as androgen deprivation or AR targeting - by restoring the nuclear receptor signaling by means of multiple mechanisms. Alternatively, tumor cells might become resistant to targeted therapies by exploiting lineage plasticity and activating alternative pathways. This review will discuss the main mechanisms leading to the emergence of resistance to therapy in prostate cancer patients in the context of genomic and molecular features of CRPC and on their causal role in the development of resistance.

Keywords

Prostate cancer / cancer evolution / resistance mechanisms / androgen receptor / metastases / castration resistant prostate cancer / genomics / epigenetics

References

[1] Siegel RL,Jemal A.Cancer statistics, 2018..CA Cancer J Clin2018;68:7-30

[2] Huggins C.Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate..CA Cancer J Clin1972;22:232-40

[3] Huggins ML.A new society for x-ray and electron diffraction research workers..Science1941;93:489-90

[4] Barrie SE,Goddard PM,Dowsett M.Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase)..J Steroid Biochem Mol Biol1994;50:267-73

[5] Chan FC,Barrie SE,Rowlands MG.3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer..J Med Chem1996;39:3319-23

[6] Potter GA,Jarman M.Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer..J Med Chem1995;38:2463-71

[7] Tran C,Clegg NJ,Watson PA.Development of a second-generation antiandrogen for treatment of advanced prostate cancer..Science2009;324:787-90 PMCID:PMC2981508

[8] Rubin MA.The genomics of prostate cancer: a historic perspective..Cold Spring Harb Perspect Med2018;

[9] Cancer Genome Atlas Research NetworkThe molecular taxonomy of primary prostate cancer..Cell2015;163:1011-25 PMCID:PMC4695400

[10] Rubin MA,Demichelis F.Genomic correlates to the newly proposed grading prognostic groups for prostate cancer..Eur Urol2016;69:557-60

[11] Barbieri CE,Lawrence MS,Blattner M.Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer..Nat Genet2012;44:685-9 PMCID:PMC3673022

[12] Gandellini P,Rancati T,Doldi V.Core biopsies from prostate cancer patients in active surveillance protocols harbor PTEN and MYC alterations..European Urology Oncology. Forthcoming2019;

[13] Camacho N,Edwards S,Matthews L.Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data..PLoS Genet2017;13:e1007001 PMCID:PMC5628936

[14] Hieronymus H,Gopalan A,Chang MT.Copy number alteration burden predicts prostate cancer relapse..Proc Natl Acad Sci U S A2014;111:11139-44 PMCID:PMC4121784

[15] Baca SC,Lawrence MS,Romanel A.Punctuated evolution of prostate cancer genomes..Cell2013;153:666-77 PMCID:PMC3690918

[16] Fraser M,Yamaguchi TN,Livingstone J.Genomic hallmarks of localized, non-indolent prostate cancer..Nature2017;541:359-64

[17] Jaratlerdsiri W,Petersen DC,Croucher PI.Next generation mapping reveals novel large genomic rearrangements in prostate cancer..Oncotarget2017;8:23588-602 PMCID:PMC5410329

[18] Quigley DA,Zhao SG,Aggarwal R.Genomic hallmarks and structural variation in metastatic prostate cancer..Cell2018;174:758-69.e9

[19] Robinson D,Wu YM,Lonigro RJ.Integrative clinical genomics of advanced prostate cancer..Cell2015;161:1215-28 PMCID:PMC4484602

[20] Robinson DR,Lonigro RJ,Cobain E.Integrative clinical genomics of metastatic cancer..Nature2017;548:297-303 PMCID:PMC5995337

[21] Wedge DC,Mitchell T,Martincorena I.Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets..Nat Genet2018;50:682-92 PMCID:PMC6372064

[22] Armenia J,Liu D,Kundra R.The long tail of oncogenic drivers in prostate cancer..Nat Genet2018;50:645-51 PMCID:PMC6107367

[23] Grasso CS,Robinson DR,Dhanasekaran SM.The mutational landscape of lethal castration-resistant prostate cancer..Nature2012;487:239-43 PMCID:PMC3396711

[24] Kumar A,MacKenzie AP,Lee C.Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers..Proc Natl Acad Sci U S A2011;108:17087-92 PMCID:PMC3193229

[25] Watson PA,Sawyers CL.Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer..Nat Rev Cancer2015;15:701-11 PMCID:PMC4771416

[26] Visakorpi T,Koivisto P,Keinanen R.In vivo amplification of the androgen receptor gene and progression of human prostate cancer..Nat Genet1995;9:401-6

[27] Menon R,Ruenauver K,Peifer M.Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer..J Pathol2013;231:505-16

[28] Robinson D,Wu YM,Lonigro RJ.Integrative clinical genomics of advanced prostate cancer..Cell2015;161:1215-28 PMCID:PMC4484602

[29] Linja MJ,Saramaki OR,Vessella RL.Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer..Cancer Res2001;61:3550-5

[30] Palmberg C,Kakkola L,Kallioniemi OP.Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer..J Urol2000;164:1992-5

[31] Waltering KK,Sahu B,Linja MJ.Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens..Cancer Res2009;69:8141-9

[32] Chen CD,Tran C,Chen R.Molecular determinants of resistance to antiandrogen therapy..Nat Med2004;10:33-9

[33] Viswanathan SR,Hoff AM,Carrot-Zhang J.Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing..Cell2018;174:433-47.e19 PMCID:PMC6046279

[34] Takeda DY,Seo JH,O’Connor E.A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer..Cell2018;174:422-32.e13 PMCID:PMC6046260

[35] Beltran H,Frampton GM,Downing SR.Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity..European urology2013;63:920-6 PMCID:PMC3615043

[36] Taplin ME,Shuster TD,Spooner AE.Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer..N Engl J Med1995;332:1393-8

[37] Azad AA,Wyatt AW,Le Bihan S.Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer..Clin Cancer Res2015;21:2315-24

[38] Conteduca V,Sharabiani MTA,Fernandez-Perez MP.Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study..Ann Oncol2017;28:1508-16 PMCID:PMC5834043

[39] Romanel A,Conteduca V,Casiraghi N.Plasma AR and abiraterone-resistant prostate cancer..Sci Transl Med2015;7:312re10 PMCID:PMC6112410

[40] Wyatt AW,Volik SV,Beja K.Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer..JAMA Oncol2016;2:1598-606 PMCID:PMC5097690

[41] Carreira S,Goodall J,Ferraldeschi R.Tumor clone dynamics in lethal prostate cancer..Sci Transl Med2014;6:254ra125 PMCID:PMC4422178

[42] Joseph JD,Qian J,Shao G.A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509..Cancer Discov2013;3:1020-9

[43] Veldscholte J,Kuiper GG,Berrevoets C.A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens..Biochem Biophys Res Commun1990;173:534-40

[44] Balbas MD,Hosfield DJ,Arora VK.Overcoming mutation-based resistance to antiandrogens with rational drug design..Elife2013;2:e00499 PMCID:PMC3622181

[45] Chen EJ,Gao S,Voznesensky O.Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors..Clin Cancer Res2015;21:1273-80 PMCID:PMC4359958

[46] Zhao XY,Krishnan AV,Navone NM.Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor..Nat Med2000;6:703-6

[47] Tan J,Hamil KG,Zang DY.Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells..Mol Endocrinol1997;11:450-9

[48] Dehm SM,Heemers HV,Tindall DJ.Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance..Cancer Res2008;68:5469-77 PMCID:PMC2663383

[49] Hu R,Wei S,Veltri RW.Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer..Cancer Res2009;69:16-22 PMCID:PMC2614301

[50] Lu J,Nacusi LP,Schmidt LJ.The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells..J Urol2015;193:690-8 PMCID:PMC4411637

[51] Chan SC,Li Y,Miao L.Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies..Nucleic Acids Res2015;43:5880-97 PMCID:PMC4499120

[52] Guo Z,Sun F,Linn DE.A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth..Cancer Res2009;69:2305-13 PMCID:PMC2672822

[53] Li Y,Fan D,Tewfik AH.Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression..Cancer Res2011;71:2108-17 PMCID:PMC3059379

[54] Li Y,Oseth LA,Vessella RL.AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression..Oncogene2012;31:4759-67 PMCID:PMC3337879

[55] Henzler C,Yang R,Ho Y.Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer..Nat Commun2016;7:13668 PMCID:PMC5141345

[56] Liu LL,Sun S,Mostaghel E.Mechanisms of the androgen receptor splicing in prostate cancer cells..Oncogene2014;33:3140-50 PMCID:PMC4553036

[57] Hornberg E,Crnalic S,Stattin P.Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival..PLoS One2011;6:e19059 PMCID:PMC3084247

[58] Miyamoto DT,Wittner BS,Zhu H.RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance..Science2015;349:1351-6 PMCID:PMC4872391

[59] Antonarakis ES,Wang H,Nakazawa M.AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer..N Engl J Med2014;371:1028-38

[60] Efstathiou E,Wen S,Karlou M.Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer..Eur Urol2015;67:53-60 PMCID:PMC4247811

[61] Antonarakis ES,Luber B,Chen Y.Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide..J Clin Oncol2017;35:2149-56 PMCID:PMC5493048

[62] Del Re M,Crucitta S,Rofi E.The Detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients..Eur Urol2017;71:680-7

[63] Scher HI,Schreiber NA,Graf RP.Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer..JAMA Oncol2016;2:1441-9 PMCID:PMC5206761

[64] Scher HI,Schreiber NA,Winquist E.Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer..JAMA Oncol2018;4:1179-86 PMCID:PMC6139066

[65] To SQ,Fettke HC,Docanto MM.Expression of androgen receptor splice variant 7 or 9 in whole blood does not predict response to androgen-axis-targeting agents in metastatic castration-resistant prostate cancer..Eur Urol2018;73:818-21

[66] Li Y,Brand LJ,Silverstein KA.Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines..Cancer Res2013;73:483-9 PMCID:PMC3549016

[67] Watson PA,Balbas MD,Socci ND.Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor..Proc Natl Acad Sci U S A2010;107:16759-65 PMCID:PMC2947883

[68] Cai L,Wang P,Li D.ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 in castrate-resistant prostate cancer..Mol Cell2018;72:341-54.e6 PMCID:PMC6214474

[69] Chen Z,Thomas-Ahner JM,Zhao P.Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13..Proc Natl Acad Sci U S A2018;115:6810-5 PMCID:PMC6042123

[70] Montgomery RB,Vessella R,Kalhorn TF.Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth..Cancer Res2008;68:4447-54 PMCID:PMC2536685

[71] Nishiyama T,Takahashi K.The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer..Clin Cancer Res2004;10:7121-6

[72] Chang KH,Kuri B,Roehrborn CG.A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer..Cell2013;154:1074-84 PMCID:PMC3931012

[73] Kumar A,Morrissey C,True LD.Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer..Nat Med2016;22:369-78 PMCID:PMC5045679

[74] Taylor BS,Hieronymus H,Xiao Y.Integrative genomic profiling of human prostate cancer..Cancer Cell2010;18:11-22 PMCID:PMC3198787

[75] Hodgson MC,Cheng S,Verhoeven MC.The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists..J Biol Chem2005;280:6511-9

[76] Lu NZ,Burnstein KL,Fuller PJ.International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors..Pharmacol Rev2006;58:782-97

[77] Arora VK,Murali R,Wongvipat J.Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade..Cell2013;155:1309-22 PMCID:PMC3932525

[78] Sahu B,Pihlajamaa P,Sinielnikov I.FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells..Cancer Res2013;73:1570-80

[79] Grindstad T,Al-Saad S,Kiselev Y.High progesterone receptor expression in prostate cancer is associated with clinical failure..PLoS One2015;10:e0116691 PMCID:PMC4344236

[80] Aparicio A,Maity SN.Understanding the lethal variant of prostate cancer: power of examining extremes..Cancer Discov2011;1:466-8 PMCID:PMC4133693

[81] Beltran H,Park K,Milowsky MI.Challenges in recognizing treatment-related neuroendocrine prostate cancer..J Clin Oncol2012;30:e386-9

[82] Beltran H,Aparicio A,Rickman D.Aggressive variants of castration-resistant prostate cancer..Clin Cancer Res2014;20:2846-50 PMCID:PMC4040316

[83] Wang HT,Li BG,Chang JW.Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis..J Clin Oncol2014;32:3383-90

[84] Aggarwal R,Alumkal JJ,Feng FY.Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study..J Clin Oncol2018;36:2492-503 PMCID:PMC6366813

[85] Bluemn EG,Lucas JM,Hernandez-Lopez S.Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling..Cancer Cell2017;32:474-89.e6 PMCID:PMC5750052

[86] Zou M,Mitrofanova A,Hayati S.Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer..Cancer Discov2017;7:736-49 PMCID:PMC5501744

[87] Beltran H,Mosquera JM,Puca L.Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer..Nat Med2016;22:298-305 PMCID:PMC4777652

[88] Ku SY,Wang Y,Seshadri M.Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance..Science2017;355:78-83 PMCID:PMC5367887

[89] Mu P,Benelli M,Hoover E.SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer..Science2017;355:84-8 PMCID:PMC5247742

[90] Bishop JL,Vahid S,Ketola K.The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer..Cancer Discov2017;7:54-71

[91] Park JW,Sheu KM,Balanis NG.Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage..Science2018;362:91-5

[92] Beltran H,Park K,Sboner A.Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets..Cancer Discovery2011;1:487-95 PMCID:PMC3290518

[93] Dardenne E,Benelli M,Berger A.N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer..Cancer Cell2016;30:563-77 PMCID:PMC5540451

[94] Wang W.Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases..Am J Surg Pathol2008;32:65-71

[95] Johnson MH,Alshalalfa M,Yousefi K.SPINK1 defines a molecular subtype of prostate cancer in men with more rapid progression in an at risk, natural history radical prostatectomy cohort..J Urol2016;196:1436-44

[96] Leinonen KA,Bracken H,Tammela TL.Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer..Clin Cancer Res2010;16:2845-51

[97] Pan X,Gong J,Yin X.The expression profile and prognostic value of SPINK1 in initially diagnosed bone metastatic prostate cancer..Prostate2016;76:823-33

[98] Tomlins SA,Yu J,Mehra R.The role of SPINK1 in ETS rearrangement-negative prostate cancers..Cancer Cell2008;13:519-28 PMCID:PMC2732022

[99] Shukla S,Murphy DA,Ran L.Aberrant activation of a gastrointestinal transcriptional circuit in prostate cancer mediates castration resistance..Cancer Cell2017;32:792-806.e7 PMCID:PMC5728174

[100] Chesire DR,Sauvageot J,Isaacs WB.Detection and analysis of beta-catenin mutations in prostate cancer..Prostate2000;45:323-34

[101] Voeller HJ,Gelmann EP.Beta-catenin mutations in human prostate cancer..Cancer Res1998;58:2520-3

[102] Chen G,Potti A,Aprikian A.Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications..Cancer2004;101:1345-56

[103] Chesire DR,Gage WR.In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis..Oncogene2002;21:2679-94

[104] Truica CI,Gelmann EP.Beta-catenin affects androgen receptor transcriptional activity and ligand specificity..Cancer Res2000;60:4709-13

[105] Yang F,Sharma M,Longo DL.Linking beta-catenin to androgen-signaling pathway..J Biol Chem2002;277:11336-44

[106] Nava Rodrigues D,Romanel A,Miranda S.RB1 heterogeneity in advanced metastatic castration-resistant prostate cancer..Clin Cancer Res2019;25:687-97

[107] Hua JT,Guo H,Chen S.Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19..Cell2018;174:564-75.e18

[108] Khurana E,Chakravarty D,Rubin MA.Role of non-coding sequence variants in cancer..Nat Rev Genet2016;17:93-108

[109] Gao P,Sipeky C,Zhang Q.Biology and clinical implications of the 19q13 aggressive prostate cancer susceptibility locus..Cell2018;174:576-89.e18 PMCID:PMC6091222

[110] Romanel A,Stringa B,Dalfovo D.Inherited determinants of early recurrent somatic mutations in prostate cancer..Nat Commun2017;8:48 PMCID:PMC5491529

[111] Mateo J,Sandhu S,Mossop H.DNA-repair defects and olaparib in metastatic prostate cancer..N Engl J Med2015;373:1697-708 PMCID:PMC5228595

[112] Wu YM,Lonigro RJ,Reimers MA.Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer..Cell2018;173:1770-82.e14 PMCID:PMC6084431